Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclo Therapeutics Inc
(NQ:
CYTH
)
0.7699
-0.0398 (-4.92%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyclo Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder
July 30, 2021
Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a...
Via
Benzinga
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
July 30, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
July 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 22, 2021
Gainers vTv Therapeutics (NASDAQ:VTVT) shares rose 30.08% to $3.07 during Tuesday's pre-market session. The company's market cap stands at $251.7 million. Adial...
Via
Benzinga
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
June 21, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo
June 17, 2021
Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The...
Via
Benzinga
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
June 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Launch of New Website
June 15, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
June 14, 2021
Gainers RAPT Therapeutics (NASDAQ:RAPT) s...
Via
Benzinga
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
June 14, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
June 09, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 24, 2021
Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market session. The market value of their outstanding shares is...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 21, 2021
Gainers Gracell Biotechnologies (NASDAQ:GRCL) shares rose 21.25% to $17.69 during Friday's regular session. Trading volume for Gracell Biotechnologies's stock is...
Via
Benzinga
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
May 20, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 17, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
May 11, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
April 27, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
55 Biggest Movers From Friday
May 03, 2021
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired...
Via
Benzinga
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
April 20, 2021
From
Cyclo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
April 12, 2021
Gainers Intec Pharma (NASDAQ:NTEC) shares increased by 7.67% to $4.35 during Monday's after-market session. Intec Pharma's trading volume hit 412 shares by close,...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.